How to Help Your Patients Save Money on Evamist: A Provider's Guide to Savings Programs

Evamist (estradiol transdermal spray) is the only FDA-approved transdermal estrogen spray, but with no generic equivalent and a retail price exceeding $180 per bottle, cost is a real barrier for many patients. This guide gives providers the information they need to help their patients access Evamist affordably — including the manufacturer's savings program, insurance optimization strategies, and resources for uninsured patients.

Understanding Evamist's Cost Structure

Evamist is a brand-name-only product. There is no FDA-approved generic estradiol transdermal spray, meaning patients cannot benefit from generic substitution. Key pricing facts:

Average retail price: ~$180.50 per bottle (56 sprays)

GoodRx discounted price: As low as $75 per bottle (58% off retail)

Manufacturer's program: As low as $25 for commercially insured patients; up to $70 savings for cash payers

No generic available: Generic estradiol spray does not exist as of 2026

The Evamist Patient Savings Program (Padagis)

The most powerful savings tool for eligible patients is the Evamist Patient Savings Program, offered by Padagis:

Commercially insured patients: May pay as little as $25 per prescription (maximum savings of $70 per fill)

Cash-paying uninsured patients: Can save up to $70 per prescription

Not available for: Medicare, Medicaid, VA, TRICARE, or other government programs

Enrollment: Patients call 1-844-415-0672 or visit evamist.com

Advise your commercially insured patients to always bring their savings card to the pharmacy before paying — the program can dramatically reduce the out-of-pocket cost.

Optimizing Insurance Coverage for Evamist

Evamist is covered by many commercial plans and some Medicare Part D plans, but tier placement varies significantly. Here are strategies to maximize coverage:

Prior authorization (PA): Many plans require PA for brand-name HRT. Submit PAs proactively and include documentation of failed alternatives if required by the plan (step therapy). For patients who failed due to the patch shortage, document this clearly.

Letter of medical necessity: A brief letter explaining why the patient requires Evamist specifically (e.g., preference for non-adhesive transdermal delivery, tolerance history with spray formulation) can support PA approval.

Step therapy exceptions: If the plan requires trying generic transdermal patches first, document that patches are in shortage and unavailable as a legitimate step therapy exception.

Medicare patients: The Padagis savings program is not available for Medicare patients. Encourage Medicare patients to compare Part D plans at plan's open enrollment to find one that covers Evamist at the lowest tier.

For Uninsured or Underinsured Patients

Uninsured patients have several cost-reduction options:

Padagis savings program: Saves up to $70/fill for cash-paying patients — significantly reduces the $180+ retail cost

GoodRx and SingleCare: Discount coupons available at goodrx.com and singlecare.com; GoodRx has reported prices as low as $75 per bottle

NeedyMeds.org and RxAssist.org: Directories of patient assistance programs for patients who meet income criteria

Consider prescribing alternatives with generic availability: If cost is a barrier, oral estradiol (generic Estrace) or generic estradiol patches (when available) cost significantly less. Discuss the clinical tradeoffs with the patient.

Mail-Order to Reduce Refill Costs and Improve Access

For patients with insurance mail-order benefits, a 90-day supply through mail-order typically costs 2.5x the monthly copay (saving approximately one month's copay every quarter). This simultaneously reduces cost and improves supply reliability — both important for Evamist.

Helping Patients Find Evamist and Access Savings

Once cost is addressed, patients still need to locate a pharmacy that has Evamist in stock. medfinder for providers calls pharmacies near your patient to check availability and texts results — reducing the patient's logistical burden. See also our companion guide: Evamist shortage: what providers need to know.